Evidence map›Paper›PMID 38584600›Full record

ArticleFrontiers in pharmacology2024

A randomized, double-blind, positive-controlled, Phase-II clinical trial to evaluate efficacy and safety of Fuke Qianjin capsule in Pakistani patients with pelvic inflammatory disease.

Muhammad Raza Shah, Sehrosh Naz Khan, Samreen Fatima, Liangyuan Yao, Hongbo Yuan, Shafi Ullah, Jahanara Ainuddin, Changqing Zeng, Yiyang Zheng, Najmus Sahar and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Muhammad Raza ShahCenter for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Sehrosh Naz Khan *Center for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Samreen FatimaCenter for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Liangyuan Yao *Qianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Hongbo Yuan *Qianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Shafi UllahCenter for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Jahanara AinuddinObstetrics and Gynecology Department, Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Changqing ZengQianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Yiyang ZhengQianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Najmus SaharThe Creek General Hospital, Karachi, Pakistan.
Shaista AnwarThe Creek General Hospital, Karachi, Pakistan.
Meijun ZhuQianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Cun MaQianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.
Kaweeta KumariThe Creek General Hospital, Karachi, Pakistan.
Wei WangCenter for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Ruihuan LiuQianjin Research Institute, Zhuzhou Qianjin Pharmaceutical Co., Ltd., Zhuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

double-blinddoxycycline hyclate tabletFuke Qianjin capsulemetronidazole tabletsparallel-controlledpelvic inflammatory diseaserandomized clinical trialtraditional Chinese medicine

Identifiers

PMID38584600
PMCPMC10995302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.